Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.68 |
| ▸ | CES1 | P23141 | 2/20 | 0.68 |
| ▸ | PARP1 | P09874 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3002929 | 0.83 | CA12 (0.65) | CES2CES1PARP1HDAC6CA12 | |
| SCHEMBL3169331 | 0.81 | CES2 (1.00) | CES2CES1PARP1HDAC1HDAC6 | |
| SCHEMBL1258944 | 0.81 | CES2 (0.74) | CES2CES1PARP1HDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL27733562 | 0.79 | CES2 (0.71) | CES2CES1PARP1HDAC1HDAC6 | |
| SCHEMBL13950378 | 0.79 | CES2 (0.71) | CES2CES1PARP1HDAC1HDAC6 | |
| SCHEMBL10703733 | 0.79 | CES2 (0.71) | CES2CES1PARP1HDAC1HDAC6 | |
| SCHEMBL29665004 | 0.79 | CES2 (0.71) | CES2CES1PARP1HDAC1HDAC6 | |
| SCHEMBL28396 | 0.79 | CES2 (0.71) | CES2CES1PARP1HDAC1HDAC6 | |
| SCHEMBL2705684 | 0.79 | CES2 (0.71) | CES2CES1PARP1HDAC1HDAC6 | |
| SCHEMBL2163731 | 0.79 | CES2 (0.71) | CES2CES1PARP1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-07-18 | — | — | US | disclosed |
| US-8445684-B2 | Nicotinic acetylcholine receptor ligands and the uses thereof | PsycoGenics Inc. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445684-B2 | Nicotinic acetylcholine receptor ligands and the uses thereof | PsycoGenics Inc. (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2305651-A1 | 2,3,6-trisubstituted-4-pyrimidone derivatives | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010045212-A2 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INCSTATUTS (US) | 2010-04-22 | — | — | WO | disclosed |
| US-5204482-A | Ethylenediamine monoamide heteroaryl derivatives | HOFFMAN-LAROCHE INC. (US) | 1993-04-20 | — | — | US | disclosed |
| US-5011849-A | Monoamine oxidase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 1991-04-30 | — | — | US | disclosed |
| US-4014909-A | ANTIIFLAMMATORY AGENTS | JOUVEINAL S.A. (FR) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | CES2 487/4885CES1 1024/4885PARP1 3529/4885 |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | CES2 487/4885CES1 1024/4885PARP1 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.